Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EPS (Weighted Average and Diluted): 2021-2024

Historic EPS (Weighted Average and Diluted) for Monte Rosa Therapeutics (GLUE) over the last 4 years, with Dec 2024 value amounting to -$0.98.

  • Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) fell 13.79% to -$0.33 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.32, marking a year-over-year increase of 117.58%. This contributed to the annual value of -$0.98 for FY2024, which is 62.74% up from last year.
  • Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.98 in FY2024, which was up 62.74% from -$2.63 recorded in FY2023.
  • Over the past 5 years, Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) peaked at -$0.98 during FY2024, and registered a low of -$2.96 during FY2021.
  • Its 3-year average for EPS (Weighted Average and Diluted) is -$1.97, with a median of -$2.30 in 2022.
  • As far as peak fluctuations go, Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) dropped by 14.35% in 2023, and later soared by 62.74% in 2024.
  • Yearly analysis of 4 years shows Monte Rosa Therapeutics' EPS (Weighted Average and Diluted) stood at -$2.96 in 2021, then rose by 22.30% to -$2.30 in 2022, then declined by 14.35% to -$2.63 in 2023, then surged by 62.74% to -$0.98 in 2024.